Eosinophilia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
George Leef (talk | contribs) No edit summary |
George Leef (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
*Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases | *Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases | ||
*If the severely elevated eosinophilia count is felt to be the cause of the patient's symptoms, there are a number of treatments that specifically lower eosinophil counts | *If the severely elevated eosinophilia count is felt to be the cause of the patient's symptoms, there are a number of treatments that specifically lower eosinophil counts | ||
*Anti-IL5 antibody [[ | *Anti-IL5 antibody [[Mepolizumab]] is under investigation for use in hypereosinophil syndrome. Mepolizumab has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids. <ref>Rothenberg et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. NEJM 2008; 358:1215-1228</ref> | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Laboratory Test]] | [[Category:Laboratory Test]] | ||
Revision as of 22:39, 29 August 2016
|
Eosinophilia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Eosinophilia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Eosinophilia future or investigational therapies |
|
Eosinophilia future or investigational therapies in the news |
|
Risk calculators and risk factors for Eosinophilia future or investigational therapies |
- Eosinophilia is a laboratory finding and is not specifically a target of treatment in most cases
- If the severely elevated eosinophilia count is felt to be the cause of the patient's symptoms, there are a number of treatments that specifically lower eosinophil counts
- Anti-IL5 antibody Mepolizumab is under investigation for use in hypereosinophil syndrome. Mepolizumab has shown potential to rapidly reduce eosinophil counts in trials and reduce the need for corticosteroids. [1]
References
- ↑ Rothenberg et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. NEJM 2008; 358:1215-1228